GT Biopharma, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 26, 2024. GT Biopharma is a clinical-stage biopharmaceutical company developing TriKE immune-cell engager therapies. It has no approved products and generated no product revenue.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.5 million | $8.8 million |
| Selling, general and administrative expense | $7.1 million | $12.4 million |
| Operating loss | $13.6 million | $21.3 million |
| Net loss | $7.6 million | $20.9 million |
| Net loss per share, basic and diluted | $5.64 | $19.66 |
| Cash used in operating activities | $8.9 million | $15.2 million |
| Cash and cash equivalents | $1.1 million | $5.7 million |
| Short-term investments | $12.9 million | $10.8 million |
Gross margin is not applicable because the company reported no revenue. The lower net loss chiefly reflects a $4.8 million noncash gain from remeasuring warrant liabilities, alongside lower operating expenses; it should not be read as a comparable improvement in underlying operating performance. The filing reports $14.0 million of combined cash and short-term investments, $7.4 million of working capital, $7.5 million of stockholders’ equity, and $6.6 million of total liabilities at year-end. Accounts payable included $3.5 million owed to the contract manufacturer. The filing does not provide a clear figure for conventional interest-bearing debt on the balance sheet.
Changes versus FY2022
- R&D expense fell $2.3 million, primarily from lower licensing and administrative costs, partly offset by increased development and production spending on GTB-3650 and GTB-5550.
- SG&A fell $5.3 million, reflecting reduced stock compensation, consulting and advisory costs, and patent and insurance costs.
- Net loss narrowed by $13.3 million, while operating loss narrowed by $7.7 million. The difference includes the larger warrant fair-value gain in 2023.
- Operating cash use decreased by $6.4 million. Cash and cash equivalents declined by $4.6 million, as operating and investment cash uses exceeded financing proceeds; the company raised $6.5 million gross in a January 2023 offering.
Business, outlook and risks
- Pipeline: GTB-3550’s Phase 1 trial enrolled 12 patients and closed in September 2021. The company reports it was generally well tolerated, with no serious cytokine-release-syndrome cases and transient reductions in marrow leukemic blasts in four patients. The company has paused further GTB-3550 development in favor of the next-generation platform.
- GTB-3650: The company submitted an IND in December 2023 and reported ongoing FDA dialogue. It anticipated FDA authorization to begin enrollment in relapsed/refractory AML and high-grade MDS in the second half of 2024.
- GTB-5550: The company was conducting preclinical work and GMP manufacturing. It anticipated an IND submission in late 2024, with a potential B7-H3-positive solid-tumor study in the first half of 2025, contingent on clinical-material supply. The filing also describes a Q4 2024 IND target.
- Spending and financing: Management estimated approximately $10 million in cash needs for the following 12 months and expected year-end cash and investments to fund operations for that period. It anticipated additional fundraising for continued trials; financing may not be available on acceptable terms. The filing reports an accumulated deficit of $682.1 million and continuing operating losses. Management concluded liquidity was adequate for at least one year from issuance, while the auditor identified the liquidity assessment as a critical audit matter.
- Development and supply risks: The company relies on third parties for research, clinical trials and manufacturing; it has no manufacturing facility, alternate supply source or commercial-scale capability, and no long-term manufacturer commitment. The University of Minnesota research agreement expired in June 2023; a replacement was under negotiation.
- Other notable items: A 1-for-30 reverse stock split became effective February 2, 2024; share and per-share figures in the filing reflect it retroactively. The company reported 1,380,633 common shares outstanding as of March 26, 2024. The auditor issued an unqualified opinion on the financial statements and identified warrant-liability valuation as another critical audit matter. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
- Contingencies: In March 2024, an arbitrator issued an interim award for the company of $409,000 and directed a former CFO to return 13,903 shares; fees remain to be determined. The company also disclosed a former executive’s retaliation complaint, for which it could not estimate the probability or range of losses, and a New York interpleader dispute over share registration. The company states it intends to defend the claims.
- Market and operating risks: The filing highlights dependence on future financing, clinical and regulatory uncertainty, potential adverse effects, competition, intellectual-property and licensing risks, limited staffing (two full-time employees and eight consultants), vendor concentration, and Nasdaq listing and share-price volatility risks.
Important facts for investors to verify
- Current cash runway, actual cash burn, and subsequent financing or dilution, including warrant and equity issuance terms.
- FDA status and timing for GTB-3650, and whether GTB-5550 manufacturing and IND milestones remain achievable.
- Clinical data and safety details for GTB-3550, and the evidence supporting the next-generation candidates.
- Contract-manufacturer payable, supply availability, and the terms or status of a renewed University of Minnesota research agreement.
- Updates on the disclosed legal matters, including final arbitration fees and resolution of the share-registration dispute.
- Post-reverse-split share count, warrant overhang, and continued compliance with Nasdaq listing requirements.